Lassen Therapeutics is a clinical stage pharmaceutical company developing antibody therapies for fibrotic diseases.

Lassen is developing a first-in-class antibody therapy suppressing IL-11 signaling to treat several fibrotic and inflammatory diseases ranging from pulmonary fibrosis to heart failure. Lassen’s antibody has an immaculate safety profile and is beginning testing in clinical trials for thyroid eye disease. Should it prove effective, Lassen’s therapeutic could become the new standard of care in both active (inflammatory) and chronic (fibrotic) thyroid eye disease, markets worth several billion dollars each.